Table 1. Ongoing trials for genomic-based early detection tests.
MCED: multicancer early detection
| Clinical trial ID | Sponsor | Trial name | Estimated enrollment | Condition | Age eligibility (years) | Status | Estimated date of completion |
| NCT05366881 | Adela Inc | CAMPERR | 7,000 | MCED | ≥40 | Recruiting | 2026-12 |
| NCT05227534 | Burning Rock | PREVENT | 12,500 | MCED | 40-75 | Recruiting | 2028-12-31 |
| NCT04825834 | DELFI Diagnostics | DELFI-L101 | 2,660 | Lung | ≥50 | Recruiting | 2026-05-31 |
| NCT05306288 | DELFI Diagnostics | CASCADE-LUNG | 15,000 | Lung | ≥50 | Active, not recruiting | 2025-03-31 |
| NCT06122077 | Freenome | PROACT-LUNG | 20,000 | Lung | ≥50 | Recruiting | 2027-06-15 |
| NCT05516927 | Freenome | Sanderson Study | 8,000 | MCED | ≥30 | Recruiting | 2025-09-06 |
| NCT05254834 | Freenome | Vallania Study | 5,400 | MCED | ≥30 | Recruiting | 2025-06-30 |
| NCT05155605 | GRAIL | PATHFINDER-2 | 35,000 | MCED | ≥50 | Recruiting | 2027-12-31 |
| ISRCTN91431511 | GRAIL | Galleri-UK NHS | 140,000 | MCED | 50-77 | Active, not recruiting | 2026-02-28 |
| NCT05205967 | GRAIL | REFLECTION | 17,000 | MCED | ≥22 | Recruiting | 2026-08-23 |
| NCT03085888 | GRAIL | STRIVE | 99,481 | Breast | ≥18 | Active, not recruiting | 2025-05 |
| NCT03934866 | GRAIL | SUMMIT | 13,035 | Lung | 55-77 | Active, not recruiting | 2030-08 |
| NCT03774758 | Guardant Health | 17–22915 | 590 | Lung | ≥40 | Recruiting | 2024-12-31 |
| NCT05181826 | Helio Health | ELITE | 1,200 | Cancer-free, benign | ≥18 | Recruiting | 2025-12 |
| NCT05199259 | Helio Health | LIVER-1 | 1,200 | Liver | ≥18 | Recruiting | 2025-03 |
| NCT05432128 | Singlera Genomics | 2019YFC1315803 | 600 | Lung | 18-75 | Recruiting | 2025-12-31 |
| NCT05485077 | Singlera Genomics | KYS-2022007 | 18,000 | Colorectal | ≥40 | Recruiting | 2028-07-09 |